The Challenge of CMC Regulatory Compliance for Biopharmaceuticals
An effective CMC regulatory compliance strategy for biologics and biopharmaceuticals can seem like a mystery. Through means of this 2nd edition, this no longer needs to occur. A great deal of thanks goes to two regulatory authorities – the United States Food and Drug Administration (FDA) and the E...
Tallennettuna:
| Päätekijä: | |
|---|---|
| Yhteisötekijä: | |
| Aineistotyyppi: | Elektroninen E-kirja |
| Kieli: | English |
| Julkaistu: |
New York, NY :
Springer New York : Imprint: Springer,
2013.
|
| Painos: | 2nd ed. 2013. |
| Aiheet: | |
| Linkit: | https://doi.org/10.1007/978-1-4614-6916-2 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|
Sisällysluettelo:
- Complexity of Biologica CMC Regulation
- Biologics are Not Chemical Drugs
- An Effective CMC Strategy is Possible
- Challenge of Adventitious Agent Control
- Source Materials for Biologics
- Manufacture of the Biologic API
- The Biologic Final Product Process
- Complex Process-Related Impurities
- Molecular Structural Analysis
- Functional Activity (Potency)
- Setting Specifications and Expiry Dates
- Demonstrating Product Comparability
- CMC-Focused Regulatory Meetings
- References.